All Hail Biopharma Market Performance
The first half of the year after a presidential election has meant losses for biopharma indices in the last three election cycles. On the heels of a year of strong performance for the sector, can momentum hold into 2013?
You may also be interested in...
Higher valuations, better quality companies, improved aftermarket performance and a broadening investor pool are all conspiring to advance the state of biotech IPOs. But VCs continue to see little step-up at IPO.
The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.